We are currently investigating intermittent issues affecting access to some articles and pages on our site. We apologize for any inconvenience and are working to resolve this as quickly as possible.

2 Cheap US Dividend Aristocrats to Buy for 2025

These reliable dividend stocks look significantly undervalued today.

Susan Dziubinski 7 January, 2025 | 8:59AM
Facebook Twitter LinkedIn

 

 

Susan Dziubinski: Hi. I’m Susan Dziubinski with Morningstar. Dividend aristocrats are companies that have raised their dividends for at least 25 consecutive years. To support this type of annual dividend growth, these companies typically maintain competitive advantages and healthy balance sheets. And because of their reliable dividend growth, the stocks of these companies often trade at or above what they’re actually worth. That’s because investors are often willing to pay a premium for dependable dividend growth.

But today, we’re looking at two dividend aristocrats whose stocks are trading well below what Morningstar thinks they’re worth. We think these dividend aristocrats look attractive heading into the new year.

2 Cheap Dividend Aristocrats to Buy for 2025

  1. Federal Realty FRT
  2. Medtronic MDT

Our first cheap dividend aristocrat to buy for 2025 is Federal Realty Trust. This REIT owns and operates shopping centers and mixed-use assets in the largest metropolitan areas. Its portfolio features very high-quality assets that are strategically located in some of the best submarkets featuring high population density and high household incomes. As a result, Federal Realty has been able to drive strong same-store net operating income growth over the past two decades. Its portfolio should continue to attract shoppers and tenants and produce solid internal growth even in a challenging retail environment. We think shares of Federal Realty are worth $142.

Read: The 10 Best Dividend Stocks

The second cheap dividend aristocrat to buy is Medtronic. The shares of one of the world’s largest medical-device companies look pretty significantly undervalued, on questions about whether the company can boost earnings growth. But Morningstar thinks Medtronic is now beginning to reap the rewards of innovation that has reached commercialization, and we expect adoption of its new therapies to support mid-single-digit growth through the midterm. We think Medtronic stock is worth $112 per share.

Visit Morningstar's Dividend Stock Investing Center

For more dividend stock ideas, be sure to subscribe to Morningstar’s channel and visit Morningstar.com.

Morningstar senior analysts Kevin Brown and Debbie Wang provided the research behind this segment.

Watch 3 of the Best Companies to Own in 2025 and Beyond for more from Susan Dziubinski.


The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar's editorial policies.

Facebook Twitter LinkedIn

About Author

Susan Dziubinski

Susan Dziubinski  is director of content for Morningstar.com.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy       Disclosures        Accessibility